Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.

Hounai Xie,Hui Wang,Lin Xu, Meng Li,Yue Peng, Xianyun Cai,Zhen Feng,Wangang Ren,Zhongmin Peng

Clinical Lung Cancer（2018）

引用 18|浏览4

暂无评分

摘要

In this retrospective study, compared to AC, gefitinib provided a statistically significant DFS benefit, reduced toxicity in EGFR mutation-positive patients with resected II-IIIA NSCLC. These results require further validation by prospective randomized trials.

查看译文

关键词

Adjuvant therapy,EGFR-TKI,Lung cancer,Survival analysis,Targeted drug

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要